Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report
Abstract Background Singleton-Merten syndrome 1 (SGMRT1) is a rare type I interferonopathy caused by heterozygous mutations in the IFIH1 gene. IFIH1 encodes the pattern recognition receptor MDA5 which senses viral dsRNA and activates antiviral type I interferon (IFN) signaling. In SGMRT1, IFIH1 muta...
Saved in:
Main Authors: | Philip Broser (Author), Ursula von Mengershausen (Author), Katrin Heldt (Author), Deborah Bartholdi (Author), Dominique Braun (Author), Christine Wolf (Author), Min Ae Lee-Kirsch (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inclusiveness and Social Justice in Evaluation: Can the Transformative Agenda Really Alter the Status Quo? A Conversation with Donna M. Mertens
by: Michele Tarsilla
Published: (2010) -
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017) -
Topical ruxolitinib for the treatment of granuloma faciale
by: Alan Wong, DO, et al.
Published: (2023) -
Ruxolitinib cream for the treatment of cutaneous sarcoidosis
by: Jeffrey S. Smith, MD, PhD, et al.
Published: (2023) -
Efficacy of topical ruxolitinib for cutaneous dermatomyositis
by: Aviya Lanis, MD, et al.
Published: (2024)